{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T16:45:22Z","timestamp":1793810722262,"version":"4.6.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,5,29]],"date-time":"2018-05-29T00:00:00Z","timestamp":1527552000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,5,29]],"date-time":"2018-05-29T00:00:00Z","timestamp":1527552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Multidrug-resistant enterococcal pathogens, especially vancomycin-resistant enterococci (VRE), are among the pathogens that require new antibiotic innovation. The colonization of the gut represents a major pathway by which VRE can cause infection and spread to other patients. In the current study, auranofin (FDA-approved rheumatoid arthritis drug) is evaluated for its potential use as a decolonizing agent for VRE. Auranofin was found to exert potent antimicrobial activity against a wide range of enterococcal clinical isolates with a minimum inhibitory concentration of 1\u2009\u03bcg\/mL. No resistant mutants could be developed against auranofin over the course of 14 passages. Auranofin was also found to exert potent anti-biofilm activity against VRE. Auranofin was superior to linezolid, the drug of choice for VRE infection treatment, in the <jats:italic>in vivo<\/jats:italic> mouse model. Auranofin significantly reduced the VRE burden in feces, cecum, and ileum contents after 8 days of treatment. Accordingly, this study provides valuable evidence that auranofin has significant promise as a novel gastrointestinal decolonizing agent for VRE.<\/jats:p>","DOI":"10.1038\/s41598-018-26674-0","type":"journal-article","created":{"date-parts":[[2018,5,23]],"date-time":"2018-05-23T15:43:15Z","timestamp":1527090195000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":72,"title":["Repurposing auranofin as an intestinal decolonizing agent for vancomycin-resistant enterococci"],"prefix":"10.1038","volume":"8","author":[{"given":"Ahmed","family":"AbdelKhalek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nader S.","family":"Abutaleb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalifa A.","family":"Elmagarmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0939-0458","authenticated-orcid":false,"given":"Mohamed N.","family":"Seleem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,29]]},"reference":[{"key":"26674_CR1","doi-asserted-by":"publisher","unstructured":"Rice, L. B. Antimicrobial resistance in gram-positive bacteria. Am J Infect Control 34, S11\u201319; discussion S64\u201373, https:\/\/doi.org\/10.1016\/j.ajic.2006.05.220 (2006).","DOI":"10.1016\/j.ajic.2006.05.220"},{"key":"26674_CR2","unstructured":"Agudelo Higuita, N. I. & Huycke, M. M. In Enterococci: From Commensals to Leading Causes of Drug Resistant Infection (eds M. S. Gilmore, D. B. Clewell, Y. Ike, & N. Shankar) (2014)."},{"key":"26674_CR3","doi-asserted-by":"publisher","first-page":"4332","DOI":"10.1172\/JCI43918","volume":"120","author":"C Ubeda","year":"2010","unstructured":"Ubeda, C. et al. Vancomycin-resistant Enterococcus domination of intestinal microbiota is enabled by antibiotic treatment in mice and precedes bloodstream invasion in humans. J Clin Invest 120, 4332\u20134341, https:\/\/doi.org\/10.1172\/JCI43918 (2010).","journal-title":"J Clin Invest"},{"key":"26674_CR4","unstructured":"Lebreton, F., Willems, R. J. L. & Gilmore, M. S. In Enterococci: From Commensals to Leading Causes of Drug Resistant Infection (eds M. S. Gilmore, D. B. Clewell, Y. Ike, & N. Shankar) (2014)."},{"key":"26674_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-14-514","volume":"14","author":"VC Cheng","year":"2014","unstructured":"Cheng, V. C. et al. Decolonization of gastrointestinal carriage of vancomycin-resistant Enterococcus faecium: case series and review of literature. BMC Infect Dis 14, 514, https:\/\/doi.org\/10.1186\/1471-2334-14-514 (2014).","journal-title":"BMC Infect Dis"},{"key":"26674_CR6","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1086\/322687","volume":"33","author":"MT Wong","year":"2001","unstructured":"Wong, M. T. et al. Effective suppression of vancomycin-resistant Enterococcus species in asymptomatic gastrointestinal carriers by a novel glycolipodepsipeptide, ramoplanin. Clin Infect Dis 33, 1476\u20131482, https:\/\/doi.org\/10.1086\/322687 (2001).","journal-title":"Clin Infect Dis"},{"issue":"Suppl 3","key":"26674_CR7","doi-asserted-by":"publisher","first-page":"iii31","DOI":"10.1093\/jac\/dkg274","volume":"51","author":"MA Montecalvo","year":"2003","unstructured":"Montecalvo, M. A. Ramoplanin: a novel antimicrobial agent with the potential to prevent vancomycin-resistant enterococcal infection in high-risk patients. J Antimicrob Chemother 51(Suppl 3), iii31\u201335, https:\/\/doi.org\/10.1093\/jac\/dkg274 (2003).","journal-title":"J Antimicrob Chemother"},{"key":"26674_CR8","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.2174\/1381612823666170209154745","volume":"23","author":"W Younis","year":"2017","unstructured":"Younis, W., AbdelKhalek, A., Mayhoub, A. S. & Seleem, M. N. In Vitro Screening of an FDA-Approved Library Against ESKAPE Pathogens. Curr Pharm Des 23, 2147\u20132157, https:\/\/doi.org\/10.2174\/1381612823666170209154745 (2017).","journal-title":"Curr Pharm Des"},{"key":"26674_CR9","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.1016\/j.bbagen.2016.09.029","volume":"1861","author":"S Thangamani","year":"2017","unstructured":"Thangamani, S. et al. Ebselen exerts antifungal activity by regulating glutathione (GSH) and reactive oxygen species (ROS) production in fungal cells. Biochim Biophys Acta 1861, 3002\u20133010, https:\/\/doi.org\/10.1016\/j.bbagen.2016.09.029 (2017).","journal-title":"Biochim Biophys Acta"},{"key":"26674_CR10","doi-asserted-by":"publisher","first-page":"4106","DOI":"10.2174\/1381612821666150506154434","volume":"21","author":"W Younis","year":"2015","unstructured":"Younis, W., Thangamani, S. & Seleem, M. N. Repurposing Non-Antimicrobial Drugs and Clinical Molecules to Treat Bacterial Infections. Curr Pharm Des 21, 4106\u20134111 (2015).","journal-title":"Curr Pharm Des"},{"key":"26674_CR11","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.2174\/1381612821666150310104416","volume":"21","author":"S Thangamani","year":"2015","unstructured":"Thangamani, S., Mohammad, H., Younis, W. & Seleem, M. N. Drug repurposing for the treatment of staphylococcal infections. Curr Pharm Des 21, 2089\u20132100 (2015).","journal-title":"Curr Pharm Des"},{"key":"26674_CR12","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s40268-015-0083-y","volume":"15","author":"C Roder","year":"2015","unstructured":"Roder, C. & Thomson, M. J. Auranofin: repurposing an old drug for a golden new age. Drugs in R&D 15, 13\u201320, https:\/\/doi.org\/10.1007\/s40268-015-0083-y (2015).","journal-title":"Drugs in R&D"},{"key":"26674_CR13","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.ijantimicag.2015.12.016","volume":"47","author":"S Thangamani","year":"2016","unstructured":"Thangamani, S., Mohammad, H., Abushahba, M. F., Sobreira, T. J. & Seleem, M. N. Repurposing auranofin for the treatment of cutaneous staphylococcal infections. Int J Antimicrob Agents 47, 195\u2013201, https:\/\/doi.org\/10.1016\/j.ijantimicag.2015.12.016 (2016).","journal-title":"Int J Antimicrob Agents"},{"key":"26674_CR14","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3389\/fcimb.2017.00004","volume":"7","author":"S Thangamani","year":"2017","unstructured":"Thangamani, S. et al. Repurposing Approach Identifies Auranofin with Broad Spectrum Antifungal Activity That Targets Mia40-Erv1 Pathway. Front Cell Infect Microbiol 7, 4, https:\/\/doi.org\/10.3389\/fcimb.2017.00004 (2017).","journal-title":"Front Cell Infect Microbiol"},{"key":"26674_CR15","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.jsb.2016.02.015","volume":"194","author":"D Parsonage","year":"2016","unstructured":"Parsonage, D. et al. X-ray structures of thioredoxin and thioredoxin reductase from Entamoeba histolytica and prevailing hypothesis of the mechanism of Auranofin action. J Struct Biol 194, 180\u2013190, https:\/\/doi.org\/10.1016\/j.jsb.2016.02.015 (2016).","journal-title":"J Struct Biol"},{"key":"26674_CR16","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1128\/AAC.01675-12","volume":"57","author":"N Tejman-Yarden","year":"2013","unstructured":"Tejman-Yarden, N. et al. A reprofiled drug, auranofin, is effective against metronidazole-resistant Giardia lamblia. Antimicrob Agents Chemother 57, 2029\u20132035, https:\/\/doi.org\/10.1128\/AAC.01675-12 (2013).","journal-title":"Antimicrob Agents Chemother"},{"key":"26674_CR17","doi-asserted-by":"publisher","first-page":"133","DOI":"10.2165\/00003088-198611020-00003","volume":"11","author":"KL Blocka","year":"1986","unstructured":"Blocka, K. L., Paulus, H. E. & Furst, D. E. Clinical pharmacokinetics of oral and injectable gold compounds. Clin Pharmacokinet 11, 133\u2013143, https:\/\/doi.org\/10.2165\/00003088-198611020-00003 (1986).","journal-title":"Clin Pharmacokinet"},{"key":"26674_CR18","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1128\/AAC.36.10.2342","volume":"36","author":"CC Johnson","year":"1992","unstructured":"Johnson, C. C., Taylor, S., Pitsakis, P., May, P. & Levison, M. E. Bactericidal activity of ramoplanin against antibiotic-resistant enterococci. Antimicrob Agents Chemother 36, 2342\u20132345 (1992).","journal-title":"Antimicrob Agents Chemother"},{"key":"26674_CR19","doi-asserted-by":"publisher","first-page":"6819","DOI":"10.1128\/AAC.00061-14","volume":"58","author":"M Cheng","year":"2014","unstructured":"Cheng, M., Huang, J. X., Ramu, S., Butler, M. S. & Cooper, M. A. Ramoplanin at bactericidal concentrations induces bacterial membrane depolarization in Staphylococcus aureus. Antimicrob Agents Chemother 58, 6819\u20136827, https:\/\/doi.org\/10.1128\/AAC.00061-14 (2014).","journal-title":"Antimicrob Agents Chemother"},{"key":"26674_CR20","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1021\/acs.jmedchem.6b01780","volume":"60","author":"H Mohammad","year":"2017","unstructured":"Mohammad, H. et al. Phenylthiazole Antibacterial Agents Targeting Cell Wall Synthesis Exhibit Potent Activity in Vitro and in Vivo against Vancomycin-Resistant Enterococci. J Med Chem 60, 2425\u20132438, https:\/\/doi.org\/10.1021\/acs.jmedchem.6b01780 (2017).","journal-title":"J Med Chem"},{"key":"26674_CR21","doi-asserted-by":"crossref","unstructured":"Garcia, L. S. & Isenberg, H. D. Clinical microbiology procedures handbook. 3rd edn, (ASM Press, 2010).","DOI":"10.1128\/9781555817435"},{"key":"26674_CR22","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1128\/AAC.01923-15","volume":"60","author":"P Seiler","year":"2015","unstructured":"Seiler, P. et al. Cadazolid Does Not Promote Intestinal Colonization of Vancomycin-Resistant Enterococci in Mice. Antimicrob Agents Chemother 60, 628\u2013631, https:\/\/doi.org\/10.1128\/AAC.01923-15 (2015).","journal-title":"Antimicrob Agents Chemother"},{"key":"26674_CR23","doi-asserted-by":"publisher","unstructured":"Mohammad, H., AbdelKhalek, A., Abutaleb, N. S. & Seleem, M. N. Repurposing niclosamide for intestinal decolonization of vancomycin-resistant enterococci. Int J Antimicrob Agents, https:\/\/doi.org\/10.1016\/j.ijantimicag.2018.02.003 (2018).","DOI":"10.1016\/j.ijantimicag.2018.02.003"},{"key":"26674_CR24","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1093\/jac\/dks469","volume":"68","author":"V Cattoir","year":"2013","unstructured":"Cattoir, V. & Leclercq, R. Twenty-five years of shared life with vancomycin-resistant enterococci: is it time to divorce? J Antimicrob Chemother 68, 731\u2013742, https:\/\/doi.org\/10.1093\/jac\/dks469 (2013).","journal-title":"J Antimicrob Chemother"},{"key":"26674_CR25","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/nrmicro2761","volume":"10","author":"CA Arias","year":"2012","unstructured":"Arias, C. A. & Murray, B. E. The rise of the Enterococcus: beyond vancomycin resistance. Nat Rev Microbiol 10, 266\u2013278, https:\/\/doi.org\/10.1038\/nrmicro2761 (2012).","journal-title":"Nat Rev Microbiol"},{"key":"26674_CR26","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1001\/archinte.158.10.1127","volume":"158","author":"MJ Bonten","year":"1998","unstructured":"Bonten, M. J. et al. The role of \u201ccolonization pressure\u201d in the spread of vancomycin-resistant enterococci: an important infection control variable. Archives of internal medicine 158, 1127\u20131132 (1998).","journal-title":"Archives of internal medicine"},{"key":"26674_CR27","doi-asserted-by":"publisher","first-page":"421","DOI":"10.4161\/viru.21282","volume":"3","author":"BL Hollenbeck","year":"2012","unstructured":"Hollenbeck, B. L. & Rice, L. B. Intrinsic and acquired resistance mechanisms in enterococcus. Virulence 3, 421\u2013433, https:\/\/doi.org\/10.4161\/viru.21282 (2012).","journal-title":"Virulence"},{"key":"26674_CR28","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1586\/14787210.2014.956092","volume":"12","author":"WR Miller","year":"2014","unstructured":"Miller, W. R., Munita, J. M. & Arias, C. A. Mechanisms of antibiotic resistance in enterococci. Expert review of anti-infective therapy 12, 1221\u20131236, https:\/\/doi.org\/10.1586\/14787210.2014.956092 (2014).","journal-title":"Expert review of anti-infective therapy"},{"key":"26674_CR29","doi-asserted-by":"publisher","first-page":"217","DOI":"10.2147\/IDR.S54125","volume":"8","author":"T O\u2019Driscoll","year":"2015","unstructured":"O\u2019Driscoll, T. & Crank, C. W. Vancomycin-resistant enterococcal infections: epidemiology, clinical manifestations, and optimal management. Infect Drug Resist 8, 217\u2013230, https:\/\/doi.org\/10.2147\/IDR.S54125 (2015).","journal-title":"Infect Drug Resist"},{"key":"26674_CR30","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1007\/s00128-007-9342-0","volume":"80","author":"RC Beier","year":"2008","unstructured":"Beier, R. C. et al. Antibiotic and disinfectant susceptibility profiles of vancomycin-resistant Enterococcus faecium (VRE) isolated from community wastewater in Texas. Bull Environ Contam Toxicol 80, 188\u2013194, https:\/\/doi.org\/10.1007\/s00128-007-9342-0 (2008).","journal-title":"Bull Environ Contam Toxicol"},{"key":"26674_CR31","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/1471-2180-6-60","volume":"6","author":"R Creti","year":"2006","unstructured":"Creti, R., Koch, S., Fabretti, F., Baldassarri, L. & Huebner, J. Enterococcal colonization of the gastro-intestinal tract: role of biofilm and environmental oligosaccharides. BMC Microbiol 6, 60, https:\/\/doi.org\/10.1186\/1471-2180-6-60 (2006).","journal-title":"BMC Microbiol"},{"key":"26674_CR32","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1099\/jmm.0.47331-0","volume":"56","author":"JA Mohamed","year":"2007","unstructured":"Mohamed, J. A. & Huang, D. B. Biofilm formation by enterococci. J Med Microbiol 56, 1581\u20131588, https:\/\/doi.org\/10.1099\/jmm.0.47331-0 (2007).","journal-title":"J Med Microbiol"},{"key":"26674_CR33","unstructured":"Ho, C., Lau, A., Cimon, K., Farrah, K. & Gardam, M. In Screening, Isolation, and Decolonization Strategies for Vancomycin-Resistant Enterococci or Extended Spectrum Beta-Lactamase Producing Organisms: A Systematic Review of the Clinical Evidence and Health Services Impact CADTH Rapid Response Reports (2012)."},{"key":"26674_CR34","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1093\/rheumatology\/36.5.560","volume":"36","author":"WF Kean","year":"1997","unstructured":"Kean, W. F., Hart, L. & Buchanan, W. W. Auranofin. Br J Rheumatol 36, 560\u2013572 (1997).","journal-title":"Br J Rheumatol"},{"key":"26674_CR35","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1093\/rheumatology\/36.8.870","volume":"36","author":"A Glennas","year":"1997","unstructured":"Glennas, A. et al. Auranofin is safe and superior to placebo in elderly-onset rheumatoid arthritis. Br J Rheumatol 36, 870\u2013877 (1997).","journal-title":"Br J Rheumatol"},{"key":"26674_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/srep22571","volume":"6","author":"S Thangamani","year":"2016","unstructured":"Thangamani, S. et al. Antibacterial activity and mechanism of action of auranofin against multi-drug resistant bacterial pathogens. Sci Rep 6, 22571, https:\/\/doi.org\/10.1038\/srep22571 (2016).","journal-title":"Sci Rep"},{"key":"26674_CR37","doi-asserted-by":"publisher","first-page":"117","DOI":"10.4155\/fmc.15.182","volume":"8","author":"BB Fuchs","year":"2016","unstructured":"Fuchs, B. B. et al. Inhibition of bacterial and fungal pathogens by the orphaned drug auranofin. Future Med Chem 8, 117\u2013132, https:\/\/doi.org\/10.4155\/fmc.15.182 (2016).","journal-title":"Future Med Chem"},{"key":"26674_CR38","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s10534-014-9743-6","volume":"27","author":"MI Cassetta","year":"2014","unstructured":"Cassetta, M. I., Marzo, T., Fallani, S., Novelli, A. & Messori, L. Drug repositioning: auranofin as a prospective antimicrobial agent for the treatment of severe staphylococcal infections. Biometals 27, 787\u2013791, https:\/\/doi.org\/10.1007\/s10534-014-9743-6 (2014).","journal-title":"Biometals"},{"key":"26674_CR39","doi-asserted-by":"publisher","first-page":"4453","DOI":"10.1073\/pnas.1504022112","volume":"112","author":"MB Harbut","year":"2015","unstructured":"Harbut, M. B. et al. Auranofin exerts broad-spectrum bactericidal activities by targeting thiol-redox homeostasis. Proc Natl Acad Sci USA 112, 4453\u20134458, https:\/\/doi.org\/10.1073\/pnas.1504022112 (2015).","journal-title":"Proc Natl Acad Sci USA"},{"key":"26674_CR40","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1128\/JB.01063-10","volume":"193","author":"M Srivastava","year":"2011","unstructured":"Srivastava, M., Mallard, C., Barke, T., Hancock, L. E. & Self, W. T. A selenium-dependent xanthine dehydrogenase triggers biofilm proliferation in Enterococcus faecalis through oxidant production. J Bacteriol 193, 1643\u20131652, https:\/\/doi.org\/10.1128\/JB.01063-10 (2011).","journal-title":"J Bacteriol"},{"issue":"Suppl 4","key":"26674_CR41","doi-asserted-by":"publisher","first-page":"iv7","DOI":"10.1093\/jac\/dkr072","volume":"66","author":"MS Dryden","year":"2011","unstructured":"Dryden, M. S. Linezolid pharmacokinetics and pharmacodynamics in clinical treatment. J Antimicrob Chemother 66(Suppl 4), iv7\u2013iv15, https:\/\/doi.org\/10.1093\/jac\/dkr072 (2011).","journal-title":"J Antimicrob Chemother"},{"key":"26674_CR42","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1002\/art.1780271121","volume":"27","author":"P Gambari","year":"1984","unstructured":"Gambari, P., Ostuni, P., Lazzarin, P., Tavolato, B. & Todesco, S. Neurotoxicity following a very high dose of oral gold (auranofin). Arthritis Rheum 27, 1316\u20131317 (1984).","journal-title":"Arthritis Rheum"},{"key":"26674_CR43","first-page":"22","volume":"128","author":"G Coppi","year":"1989","unstructured":"Coppi, G., Borella, F., Gatti, M. T., Comini, A. & Dall\u2019Asta, L. Synthesis, antiinflammatory and antiarthritic properties of a new tiopronine gold derivative. Boll Chim Farm 128, 22\u201324 (1989).","journal-title":"Boll Chim Farm"},{"key":"26674_CR44","unstructured":"(CLSI), C. a. L. S. I. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard\u2014Ninth Edition M07-A9. 32 No. 2 (January 2012)."},{"key":"26674_CR45","doi-asserted-by":"publisher","first-page":"750","DOI":"10.3389\/fmicb.2015.00750","volume":"6","author":"S Thangamani","year":"2015","unstructured":"Thangamani, S., Younis, W. & Seleem, M. N. Repurposing celecoxib as a topical antimicrobial agent. Front Microbiol 6, 750, https:\/\/doi.org\/10.3389\/fmicb.2015.00750 (2015).","journal-title":"Front Microbiol"},{"key":"26674_CR46","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.bbagen.2017.01.029","volume":"1861","author":"MF Mohamed","year":"2017","unstructured":"Mohamed, M. F., Brezden, A., Mohammad, H., Chmielewski, J. & Seleem, M. N. Targeting biofilms and persisters of ESKAPE pathogens with P14KanS, a kanamycin peptide conjugate. Biochim Biophys Acta 1861, 848\u2013859, https:\/\/doi.org\/10.1016\/j.bbagen.2017.01.029 (2017).","journal-title":"Biochim Biophys Acta"},{"key":"26674_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-07440-0","volume":"7","author":"MF Mohamed","year":"2017","unstructured":"Mohamed, M. F., Brezden, A., Mohammad, H., Chmielewski, J. & Seleem, M. N. A short D-enantiomeric antimicrobial peptide with potent immunomodulatory and antibiofilm activity against multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Sci Rep 7, 6953, https:\/\/doi.org\/10.1038\/s41598-017-07440-0 (2017).","journal-title":"Sci Rep"},{"key":"26674_CR48","doi-asserted-by":"publisher","first-page":"e0182821","DOI":"10.1371\/journal.pone.0182821","volume":"12","author":"H Mohammad","year":"2017","unstructured":"Mohammad, H. et al. Bacteriological profiling of diphenylureas as a novel class of antibiotics against methicillin-resistant Staphylococcus aureus. PLoS One 12, e0182821, https:\/\/doi.org\/10.1371\/journal.pone.0182821 (2017).","journal-title":"PLoS One"},{"key":"26674_CR49","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/ja.2014.142","volume":"68","author":"H Mohammad","year":"2015","unstructured":"Mohammad, H., Mayhoub, A. S., Cushman, M. & Seleem, M. N. Anti-biofilm activity and synergism of novel thiazole compounds with glycopeptide antibiotics against multidrug-resistant staphylococci. J Antibiot (Tokyo) 68, 259\u2013266, https:\/\/doi.org\/10.1038\/ja.2014.142 (2015).","journal-title":"J Antibiot (Tokyo)"},{"key":"26674_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/srep16407","volume":"5","author":"S Thangamani","year":"2015","unstructured":"Thangamani, S. et al. Exploring simvastatin, an antihyperlipidemic drug, as a potential topical antibacterial agent. Sci Rep 5, 16407, https:\/\/doi.org\/10.1038\/srep16407 (2015).","journal-title":"Sci Rep"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-26674-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-26674-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-26674-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T05:51:18Z","timestamp":1671601878000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-26674-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,29]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["26674"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-26674-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,29]]},"assertion":[{"value":"14 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"8353"}}